Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243202 · ClinicalTrials.gov registry record · Phase 2
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
A Phase 2 study of Obesity, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 335
- Enrollment target
- 17
- Study locations
NCT02243202 is a Phase 2 study of Obesity that has completed, run by Janssen Research & Development. The registered enrollment target is 335 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The trial reports 17 study locations across 15 states.
The verdict
NCT02243202, a Phase 2 study of Obesity, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 335 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
Conditions Studied
Interventions
- DRUG Phentermine
- DRUG Canagliflozin
- DRUG Matching Placebo to Canagliflozin
- DRUG Matching Placebo to Phentermine
Study Locations (17)
Kentucky
- - Lexington
- - Louisville
Texas
- - Dallas
- - Odessa
Arizona
- - Phoenix
California
- - Walnut Creek
Florida
- - Jacksonville
Idaho
- - Meridian
Indiana
- - Evansville
Louisiana
- - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243202
The ClinicalTrials.gov registry entry for NCT02243202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Phentermine is the first listed.
NCT02243202 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Kentucky, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT02243202 about?
NCT02243202 is a clinical study titled "Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants". The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
What is the current status of trial NCT02243202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 335 participants. The study started on 2014-09. Estimated completion is 2015-06.
What conditions does trial NCT02243202 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT02243202?
The interventions under investigation include: Phentermine (DRUG), Canagliflozin (DRUG), Matching Placebo to Canagliflozin (DRUG), Matching Placebo to Phentermine (DRUG).
Who is sponsoring clinical trial NCT02243202?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243202 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.